FHB focuses on the immune system related services and innovative R&D. Our goal is to establish the cell-based immunotherapies for cancers and autoimmune disorders.
FHB sets up a brand new 661 square meters laboratory, which is qualified with Good Tissue Practice and ISO/IEC 17025 of Taiwan Accreditation Foundation (TAF) certificated.
The mission of FHB is to persistently expand the international cooperations, promote the clinical trials and obtain the medical certificate.
FHB provides immunoprofiling, circulating tumor cells testing, regulation of cell therapy contracting immune cell manufacturing, immune cell bank and contracting research organization.
In addition to the general health examination, immunoprofiling is a well testing item to assess the possibility of disease, including cancer or other immune related disease. FHB provides several immune system services and cooperates with medical center, clinic and health care center to carry out the customized immunoprofiling analysis.
FHB has cooperated and proposed autoimmune cell therapy with several medical centers and clinics. Once received the permission of Center for Drug Evaluation (CDE), patients can be conducted the immune cell therapy in the cooperative medical institution.
FHB provides customized services of clinical trial management to satisfy each requirement of specific products, such as document preparation for IND, application of IRB/FDA/TFDA, project management of clinical trials, statistical analysis for experimental data, redaction of clinical reports, and quality control of laboratory etc.
FHB constructs a complete screening platform for circulating tumor cells based on intensive research. We utilize the advanced flow cytometer and epitope-specific monoclonal antibodies to accurately identify circulating tumor cells.
富禾生醫總經理李建謀於4月16日受台灣美容醫學產業全國聯合會邀請，擔任「再生醫療論壇」座長，與談人包含財團法人台灣醫界聯盟基金會執行長林世嘉、台北榮民總醫院腫瘤醫學部部主任趙毅、相關幹細胞專家及律師。李總經理針對再生醫療三法做重點式介紹，讓與會貴賓更了解目前法規內容；執行長林世嘉則提出台灣細胞產業發展CDMO（委託開發暨製造服務）的優勢與劣勢；部主任趙毅提出目前在臨床端癌症免疫細胞治療的醫師觀點，透過演講及交流，使與會貴賓對於目前的再生醫療現況有更清楚的了解。感謝聯合會理事長蔡豐州的引導及主持，讓此論壇專家齊聚並圓滿落幕。
今(20)日，富禾生醫宣布，其推出的「免疫療法之精準診斷及客製化治療」服務項目，獲SNQ國家品質標章續審認證。此為富禾生醫連續三年以此項目，通過財團法人生技醫療科技政策研究中心相關領域專家的肯定。
The general manager of FullHope Biomedical Co., Ltd., Dr. Lee, Jan Mou was invited by Foundation of Medical Professionals Alliance in Taiwan as the lecturer on May 2nd 2021. He took ‘’Advance of Current Immunotherapy: Past, Current and Future aspects’’ as the theme for plastic surgery doctors in Ministry of Health and Welfare Shuang-Ho Hospital. […]
The students of International Ph.D. Program for Cell Therapy and Regeneration Medicine (IPCTRM) at Taipei Medical University (TMU) visited the laboratory of FHB on Apr. 14th 2021. With the industry-academia cooperation, hoping the students had deeply understood the working space in regeneration medicine industry.
The general manager of FullHope, Co., Ltd., Dr. Lee was invited as a special lecturer by Taiwan Academy of Allergy Asthma and Clinical immunology (TAAACI) for the course of immune cell therapy on Mar. 7th 2021. Dr. Lee took “Advance of Current Immunotherapy: Past, Current and future aspects” as theme to explain profound theories in […]
